// App-Quantinova.ai

2575 : Phase I dose-escalation study of an oral administration of the pan-histonedeacetylase inhibitor abexinostat combined with a fixed dose of doxorubicin in patients with solid tumors.

Researchers

Presenter

  • Arnaud Scherpereel

Principal Investigators

  • Ahmad Awada

  • Carlos Alberto Gomez-Roca

  • Frederique Cantero

  • Marie-Capucine Willemin

  • Thierry Gil

  • Eleonora De Maio

  • Elsa Jozefowicz

  • Ioana Kloos

  • Alice Dorbon

Medical Centers

  • University Hospital of Lille Nord de France, Lille, France

  • Hospital of the University (CHU) de Lille, Lille, France

  • IRIS, Suresnes, FranceInstitut de Recherches Internationales Servier (I. R. I. S.), Suresnes, France

  • I.R.I.S, Suresnes, France

  • Institut Claudius Regaud, Toulouse, France

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

Locations

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Abexinostat

  • Doxorubicin

Outcome

  • Positive

Study Design

  • pharmacokinetics

  • fixed dose

Phase

  • I

Study Id's

  • ISRCTN55052510

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved